Literature DB >> 34239610

Antibiotic usage and stewardship in patients with COVID-19: too much antibiotic in uncharted waters?

Terry John Evans1, Harriet Claire Davidson1, Jen Mae Low1, Marina Basarab1, Amber Arnold1.   

Abstract

BACKGROUND: Antimicrobial usage and stewardship programmes during COVID-19 have been poorly studied. Prescribing practice varies despite national guidelines, and there is concern that stewardship principles have suffered. AIM: To analyse antibiotic prescriptions during the COVID-19 pandemic at a teaching hospital and to propose improved approaches to stewardship.
METHODS: We reviewed COVID-19 admissions to medical wards and intensive care units (ICUs) in a London teaching hospital to assess initial antibiotic usage and evidence of bacterial co-infection, and to determine if our current antibiotic guidelines were adhered to.
FINDINGS: Data from 130 inpatients (76% medical and 24% ICU) were obtained. On admission, 90% were treated with antibiotics. No microbiological samples taken on admission provided definitive evidence of respiratory co-infection. In 13% of cases, antibiotics were escalated, usually without supporting clinical, radiological or laboratory evidence. In 16% of cases, antibiotics were stopped or de-escalated within 72 h. Blood results and chest radiographs were characteristic of COVID-19 in 20% of ward patients and 42% of ICU patients. Overall mortality was 25% at 14 days - similar to rates described for the UK as a whole.
CONCLUSION: The majority of patients received antibiotics despite limited evidence of co-infection. Most patients received narrower spectrum antibiotics than recommended by NICE. As understanding of the natural history of COVID-19 infections progresses, stewardship programmes will need to evolve; however, at this point, we feel that a more restrictive antibiotic prescribing approach is warranted. We propose strategies for effective stewardship and estimate the effect this may have on antibiotic consumption.
© The Author(s) 2020.

Entities:  

Keywords:  Antimicrobial stewardship; COVID-19; SARS-CoV-2; coronavirus

Year:  2020        PMID: 34239610      PMCID: PMC8113669          DOI: 10.1177/1757177420976813

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  22 in total

Review 1.  Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.

Authors:  Timothy M Rawson; Luke S P Moore; Nina Zhu; Nishanthy Ranganathan; Keira Skolimowska; Mark Gilchrist; Giovanni Satta; Graham Cooke; Alison Holmes
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

Review 2.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

3.  'Matching Michigan': a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England.

Authors:  Julian Bion; Annette Richardson; Peter Hibbert; Jeanette Beer; Tracy Abrusci; Martin McCutcheon; Jane Cassidy; Jane Eddleston; Kevin Gunning; Geoff Bellingan; Mark Patten; David Harrison
Journal:  BMJ Qual Saf       Date:  2012-09-20       Impact factor: 7.035

4.  Severe COVID-19 and healthcare-associated infections on the ICU: time to remember the basics?

Authors:  A Sturdy; M Basarab; M Cotter; K Hager; D Shakespeare; N Shah; P Randall; D Spray; A Arnold
Journal:  J Hosp Infect       Date:  2020-06-23       Impact factor: 3.926

Review 5.  The hallmarks of COVID-19 disease.

Authors:  Daolin Tang; Paul Comish; Rui Kang
Journal:  PLoS Pathog       Date:  2020-05-22       Impact factor: 6.823

6.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Yeming Wang; Dingyu Zhang; Guanhua Du; Ronghui Du; Jianping Zhao; Yang Jin; Shouzhi Fu; Ling Gao; Zhenshun Cheng; Qiaofa Lu; Yi Hu; Guangwei Luo; Ke Wang; Yang Lu; Huadong Li; Shuzhen Wang; Shunan Ruan; Chengqing Yang; Chunlin Mei; Yi Wang; Dan Ding; Feng Wu; Xin Tang; Xianzhi Ye; Yingchun Ye; Bing Liu; Jie Yang; Wen Yin; Aili Wang; Guohui Fan; Fei Zhou; Zhibo Liu; Xiaoying Gu; Jiuyang Xu; Lianhan Shang; Yi Zhang; Lianjun Cao; Tingting Guo; Yan Wan; Hong Qin; Yushen Jiang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Bin Cao; Chen Wang
Journal:  Lancet       Date:  2020-04-29       Impact factor: 79.321

7.  Remdesivir for the Treatment of Covid-19 - Final Report.

Authors:  John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

8.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

Review 9.  Bacterial and viral infections associated with influenza.

Authors:  Carol Joseph; Yu Togawa; Nahoko Shindo
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

10.  Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Clin Chim Acta       Date:  2020-03-04       Impact factor: 3.786

View more
  4 in total

1.  Real-world Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention "Hotspots" in an Antibiotic Audit and Feedback Program.

Authors:  Katherine E Goodman; Emily L Heil; Kimberly C Claeys; Mary Banoub; Jacqueline T Bork
Journal:  Open Forum Infect Dis       Date:  2022-06-10       Impact factor: 4.423

2.  Evaluation of Bacterial Coinfection and Antibiotic Resistance in Patients with COVID-19 Under Mechanical Ventilation.

Authors:  Alireza Nikzad Jamnani; Mahbobeh Montazeri; Maryam Mirzakhani; Mahmood Moosazadeh; Mohammad Haghighi
Journal:  SN Compr Clin Med       Date:  2022-01-06

3.  Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic.

Authors:  Susan K Seo; Nina Cohen; Kayla R Maki; Samantha N Steiger; Yiqi Su; Aida Boumiza; Carrie A Tan; Marina Kerpelev
Journal:  Infect Control Hosp Epidemiol       Date:  2022-05-26       Impact factor: 6.520

4.  Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality.

Authors:  X H S Chan; C J O'Connor; E Martyn; A J Clegg; B J K Choy; A L Soares; R Shulman; N R H Stone; S De; J Bitmead; L Hail; D Brealey; N Arulkumaran; M Singer; A P R Wilson
Journal:  J Hosp Infect       Date:  2022-03-23       Impact factor: 8.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.